The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries
- PMID: 17077426
- DOI: 10.1192/bjp.bp.106.029983
The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries
Abstract
Most people with schizophrenia live in low- and middle-income countries in which clinicians/policy makers are not the first targets of marketing. Because it is years after a drug is first launched that the full effects become known with confidence, the evidence upon which to base practice in low- and middle-income countries may be less biased than that in richer nations.
Comment in
-
Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia.Br J Psychiatry. 2006 Nov;189:433-40. doi: 10.1192/bjp.bp.105.019307. Br J Psychiatry. 2006. PMID: 17077434 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
